Novel agents for the treatment of childhood acute leukemia

Therapeutic Advances in Hematology

Volumn 6, Issue 2, 2015, Pages 61-79

  Annesley, Colleen E ^a   Brown, Patrick ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

ALL; AML; blinatumomab; CAR T cells; carfilzomib; EPZ 5676; FLT3; moxetumomab

Indexed keywords

EID: 84993813859     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620714565963     Document Type: Review

References (144)

1. Advani A. Coiffier B. Czuczman M. Dreyling M. Foran J. Gine E. et al. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28: 2085–2093.
2. Aplenc R. Alonzo T. Sung L. Meshinchi S. Gerbing R. Raimondi S. et al. (2013) Gemtuzumab Ozogamicin (GO) in children with de Novo Acute Myeloid Leukemia (AML) improves Event-Free Survival (EFS) by reducing relapse risk – results from the randomized Phase III Children's Oncology Group (COG) trial, AAML0531. Blood 122: 355–356.
3. Arastu-Kapur S. Anderl J. Kraus M. Parlati F. Shenk K. Lee S. et al. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17: 2734–2743.
4. Armstrong S. Staunton J. Silverman L. Pieters R. den Boer M. Minden M. et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Gen 30: 41–47.
5. Attar E. de Angelo D. Supko J. D'Amato F. Zahrieh D. Sirulnik A. et al. (2008) Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 14: 1446–1454.
6. Ayton P. Cleary M. (2001) Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20: 5695–5707.
7. Bachmann P. Piazza R. Janes M. Wong N. Davies C. Mogavero A. et al. (2010) Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 116: 3013–3022.
8. Bargou R. Leo E. Zugmaier G. Klinger M. Goebeler M. Knop S. et al. (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974–977.
9. Barrett D. Singh N. Porter D. Grupp S. June C. (2014) Chimeric antigen receptor therapy for cancer. Ann Rev Med 65: 333–347.
10. Bernt K. Zhu N. Sinha A. Vempati S. Faber J. Krivtsov A. et al. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66–78.
11. Bhatla T. Wang J. Morrison D. Raetz E. Burke M. Brown P. et al. (2012) Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119: 5201–5210.
12. Brown V. Fang J. Alcorn K. Barr R. Kim J. Wasserman R. et al. (2003) Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 100: 15113–15118.
13. Burnett A. Hills R. Milligan D. Kjeldsen L. Kell J. Russell N. et al. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML 15 trial. J Clin Oncol 29: 369–377.
14. Buttner N. Johnsen S. Kugler S. Vogel T. (2010) Af9/Mllt3 interferes with Tbr 1 expression through epigenetic modification of histone H3K79 during development of the cerebral cortex. Proc Natl Acad Sci USA 107: 7042–7047.
15. Carnahan J. Wang P. Kendall R. Chen C. Hu S. Boone T. et al. (2003) Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 9: 3982S–3990S.
16. Carow C. Levenstein M. Kaufmann S. Chen J. Amin S. Rockwell P. et al. (1996) Expression of the hematopoietic growth factor receptor FLT 3 (STK-1/Flk2) in human leukemias. Blood 87: 1089–1096.
17. Castaigne S. Pautas C. Terre C. Raffoux E. Bordessoule D. Bastie J. et al. (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379: 1508–1516.
18. Chang B. Willis S. Stork L. Hunger S. Carroll W. Camitta B. et al. (2012) Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. Br J Haematol 157: 507–510.
19. Chang M. Wu H. Achille N. Reisenauer M. Chou C. Zeleznik-Le N. et al. (2010) Histone H 3 lysine 79 methyltransferase Dot 1 is required for immortalization by MLL oncogenes. Cancer Res 70: 10234–10242.
20. Chen L. Deshpande A. Banka D. Bernt K. Dias S. Buske C. et al. (2013) Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 27: 813–822.
21. Cooper T. Franklin J. Gerbing R. Alonzo T. Hurwitz C. Raimondi S. et al. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer 118: 761–769.
22. Cooper, T., Malvar J. Cassar J. Eckroth E. Sposto R. Gaynon P. Dubois S. et al. (2013) A phase I study of AC 220 (Quizartinib) in combination with cytarabine and etoposide in relapsed / refractory childhood ALL and AML: a therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood 122: 624–626.
23. Cortes J. Kim D. Pinilla-Ibarz J. Le Coutre P. Paquette R. Chuah C. et al. (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369: 1783–1796.
24. Creutzig U. Harbott J. Sperling C. Ritter J. Zimmermann M. Loffler H. et al. (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 86: 3097–3108.
25. Crump M. Hedley D. Kamel-Reid S. Leber B. Wells R. Brandwein J. et al. (2010) A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia Lymphoma 51: 252–260.
26. Daigle S. Olhava E. Therkelsen C. Majer C. Sneeringer C. Song J. et al. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20 (1): 53–65.
27. Daver N. Cortes J. (2012) Molecular targeted therapy in acute myeloid leukemia. Hematology 17(Suppl. 1): S59–S62.
28. Deshpande A. Chen L. Fazio M. Sinha A. Bernt K. Banka D. et al. (2013) Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121:2533–2541.
29. Di Joseph J. Armellino D. Boghaert E. Khandke K. Dougher M. Sridharan L. et al. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103: 1807–1814.
30. Dijoseph J. Dougher M. Armellino D. Evans D. Damle N. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21 (11): 2240–2245.
31. Fandy T. Herman J. Kerns P. Jiemjit A. Sugar E. Choi S. et al. (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114: 2764–2773.
32. Fayad L. Offner F. Smith M. Verhoef G. Johnson P. Kaufman J. et al. (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I / II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 31: 573–583.
33. Fischer T. Stone R. Deangelo D. Galinsky I. Estey E. Lanza C. et al. (2010) Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28: 4339–4345.
34. Fouladi M. Park J. Stewart C. Gilbertson R. Schaiquevich P. Sun J. et al. (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 28: 3623–3629.
35. Frey N. Aplenc R. Barrett D. Chew A. Kalos M. Levine B. et al. (2013) T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Blood 122: 67.
36. Garcia-Manero G. Assouline S. Cortes J. Estrov Z. Kantarjian H. Yang H. et al. (2008) Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112: 981–989.
37. Garcia-Manero G. Kantarjian H. Sanchez-Gonzalez B. Yang H. Rosner G. Verstovsek S. et al. (2006) Phase 1 / 2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood 108: 3271–3279.
38. Gore S. (2005) Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Nat Clin Pract Oncol 2(Suppl. 1): S30–S35.
39. Gore S. Baylin S. Sugar E. Carraway H. Miller C. Carducci M. et al. (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.
40. Grupp S. Kalos M. Barrett D. Aplenc R. Porter D. Rheingold S. et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518.
41. Gudowius S. Recker K. Laws H. Dirksen U. Troger A. Wieczorek U. et al. (2006) Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatrie 218: 327–333.
42. Guzman M. Neering S. Upchurch D. Grimes B. Howard D. Rizzieri D. et al. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301–2307.
43. Guzman M. Swiderski C. Howard D. Grimes B. Rossi R. Szilvassy S. et al. (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99: 16220–16225.
44. Handgretinger R. Zugmaier G. Henze G. Kreyenberg H. Lang P. von Stackelberg A. (2011) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25: 181–184.
45. Hasle H. Abrahamsson J. Forestier E. Ha S. Heldrup J. Jahnukainen K. et al. (2012) Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120: 978–984.
46. Haso W. Lee D. Shah N. Stetler-Stevenson M. Yuan C. Pastan I. et al. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121: 1165–1174.
47. Herman J. Civin C. Issa J. Collector M. Sharkis S. Baylin S. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57: 837–841.
48. Hinman L. Hamann P. Wallace R. Menendez A. Durr F. Upeslacis J. (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 53: 3336–3342.
49. Horton T. Pati D. Plon S. Thompson P. Bomgaars L. Adamson P. et al. (2007) A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res 13: 1516–1522.
50. Hunger S. Lu X. Devidas M. Camitta B. Gaynon P. Winick N. et al. (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 30: 1663–1669.
51. Inaba H. Rubnitz J. Coustan-Smith E. Li L. Furmanski B. Mascara G. et al. (2011) Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed / refractory leukemia. J Clin Oncol 29: 3293–3300.
52. Iwai T. Yokota S. Nakao M. Okamoto T. Taniwaki M. Onodera N. et al. (1999) Internal tandem duplication of the FLT 3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 13: 38–43.
53. Jabbour E. Kantarjian H. Jones D. Reddy N. O'Brien S. Garcia-Manero G. et al. (2008) Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112: 4839–4842.
54. Jayanthan A. Ruan Y. Hagerty M. Shah R. Truong T. Lewis V. et al. (2013) In vitro growth inhibition, target modulation and drug synergy in pediatric leukemia by the novel proteasome inhibitor carfilzomib. Blood 122: 2673–2674.
55. Kalos M. Levine B. Porter D. Katz S. Grupp S. Bagg A. et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3 (95): 95ra73.
56. Kantarjian H. Issa J. Rosenfeld C. Bennett J. Albitar M. DiPersio J. et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106: 1794–1803.
57. Kantarjian H. Thomas D. Jorgensen J. Jabbour E. Kebriaei P. Rytting M. et al. (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet Oncology 13 (4): 403–411.
58. Kantarjian H. Thomas D. Jorgensen J. Kebriaei P. Jabbour E. Rytting M. et al. (2013) Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119: 2728–2736.
59. Klinger M. Brandl C. Zugmaier G. Hijazi Y. ÍBargou R. Topp M. et al. (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119: 6226–6233.
60. Knapper S. Burnett A. Littlewood T. Kell W. Agrawal S. Chopra R. et al. (2006) A phase 2 trial of the FLT 3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108: 3262–3270.
61. Kondo M. Horibe K. Takahashi Y. Matsumoto K. Fukuda M. Inaba J. et al. (1999) Prognostic value of internal tandem duplication of the FLT 3 gene in childhood acute myelogenous leukemia. Med Pediatric Oncol 33: 525–529.
62. Kramer O. Muller S. Buchwald M. Reichardt S. Heinzel T. (2008) Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J 22: 1369–1379.
63. Kreitman R. Margulies I. Stetler-Stevenson M. Wang Q. FitzGerald D. Pastan I. (2000) Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 6: 1476–1487.
64. Krivtsov A. Feng Z. Lemieux M. Faber J. Vempati S. Sinha A. et al. (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14: 355–368.
65. Krivtsov A. Twomey D. Feng Z. Stubbs M. Wang Y. Faber J. et al. (2006) Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818–822.
66. Lacoste N. Utley R. Hunter J. Poirier G. Cote J. (2002) Disruptor of telomeric silencing-1 is a chromatin-specific histone H 3 methyltransferase. J Biol Chem 277: 30421–30424.
67. Leclerc G. Mou C. Leclerc G. Mian A. Barredo J. (2010) Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy. Leukemia 24: 552–562.
68. Levis M. Perl A. Dombret H. Dohner H. Steffen B. Rousselot P. et al. (2012) Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed / Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. ASH Annual Meeting Abstracts 120 (21): 673.
69. Levis M. Ravandi F. Wang E. Baer M. Perl A. Coutre S. et al. (2011) Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT 3 mutant AML in first relapse. Blood 117: 3294–3301.
70. Loffler A. Kufer P. Lutterbuse R. Zettl F. Daniel P. Schwenkenbecher J. et al. (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95: 2098–2103.
71. Lucas D. Alinari L. West D. Davis M. Edwards R. Johnson A. et al. (2010) The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PloS ONE 5 (6): e10941.
72. Maestre N. Tritton T. Laurent G. Jaffrezou J. (2001) Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Cancer Res 61: 2558–2561.
73. Maude S. Tasian S. Vincent T. Hall J. Sheen C. Roberts K. et al. (2012) Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120: 3510–3518.
74. Meshinchi S. Alonzo T. Stirewalt D. Zwaan M. Zimmerman M. Reinhardt D. et al. (2006) Clinical implications of FLT 3 mutations in pediatric AML. Blood 108: 3654–3661.
75. Meshinchi S. Woods W. Stirewalt D. Sweetser D. Buckley J. Tjoa T. et al. (2001) Prevalence and prognostic significance of Flt 3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97: 89–94.
76. Messinger Y. Gaynon P. Raetz E. Hutchinson R. Dubois S. Glade-Bender J. et al. (2010) Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatric Blood Cancer 55: 254–259.
77. Messinger Y. Gaynon P. Sposto R. van der Giessen J. Eckroth E. Malvar J. et al. (2012) Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia & lymphoma (TACL) study. Blood 120: 285–290.
78. Min Y. Eom J. Cheong J. Maeng H. Kim J. Jeung H. et al. (2003) Constitutive phosphorylation of Akt / PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17 (5): 995–997.
79. Mueller D. Bach C. Zeisig D. Garcia-Cuellar M. Monroe S. Sreekumar A. et al. (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110: 4445–4454.
80. Mullighan C. Zhang J. Harvey R. Collins-Underwood J. Schulman B. Phillips L. et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 106: 9414–9418.
81. Mussai F. Campana D. Bhojwani D. Stetler-Stevenson M. Steinberg S. Wayne A. et al. (2010) Cytotoxicity of the anti-CD22 immunotoxin HA 22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 150: 352–358.
82. Nguyen A. Taranova O. He J. Zhang Y. (2011) DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117: 6912–6922.
83. O'Hear C. Inaba H. Pounds S. Shi L. Dahl G. Bowman W. et al. (2013) Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 119: 4036–4043.
84. Okada Y. Feng Q. Lin Y. Jiang Q. Li Y. Coffield V. et al. (2005) hDOT1L links histone methylation to leukemogenesis. Cell 121: 167–178.
85. Parker C. Waters R. Leighton C. Hancock J. Sutton R. Moorman A. et al. (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 376: 2009–2017.
86. Pastan I. Hassan R. Fitzgerald D. Kreitman R. (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559–565.
87. Porkka K. Koskenvesa P. Lundan T. Rimpilainen J. Mustjoki S. Smykla R. et al. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112: 1005–1012.
88. Pratz K. Cho E. Levis M. Karp J. Gore S. McDevitt M. et al. (2010) A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 24: 1437–1444.
89. Press O. Farr A. Borroz K. Anderson S. Martin P. (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49: 4906–4912.
90. Pui C. Carroll W. Meshinchi S. Arceci R. (2011 a) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29: 551–565.
91. Pui C. Gajjar A. Kane J. Qaddoumi I. Pappo A. (2011 b) Challenging issues in pediatric oncology. Nat Rev Clin Oncol 8: 540–549.
92. Pulsipher M. Langholz B. Wall D. Schultz K. Bunin N. Carroll W. et al. (2014) The addition of sirolimus to tacrolimus / methotrexate GVHD prophylaxis in children with ALL: a phase 3 children's oncology group / pediatric blood and marrow transplant consortium trial. Blood 123: 2017–2025.
93. Raetz E. Cairo M. Borowitz M. Lu X. Devidas M. Reid J. et al. (2011) Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from children's oncology group (COG) study ADVL04P2. ASH Annual Meeting Abstracts 118 (21): 573.
94. Rajkumar S. Richardson P. Hideshima T. Anderson K. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630–639.
95. Ravandi F. Cortes J. Jones D. Faderl S. Garcia-Manero G. Konopleva M. et al. (2010) Phase I / II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 28: 1856–1862.
96. Ravandi F. Estey E. Appelbaum F. Lo-Coco F. Schiffer C. Larson R. et al. (2012) Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 30: 3921–3923.
97. Recher C. Beyne-Rauzy O. Demur C. Chicanne G. Dos Santos C. Mas V. et al. (2005 a) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105: 2527–2534.
98. Recher C. Dos Santos C. Demur C. Payrastre B. (2005 b) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4: 1540–1549.
99. Roberts K. Li Y. Payne-Turner D. Harvey R. Yang Y. Pei D. et al. (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371: 1005–1015.
100. Roman E. Cooney E. Harrison L. Militano O. Wolownik K. Hawks R. et al. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clin Cancer Res 11: 7164s–7170s.
101. Ruan Y. Liu D. Jayanthan A. Truong T. Boklan J. Narendran A. (2013) Abstract C205: Cytotoxicity and target modulation in pediatric solid tumors by the proteasome inhibitor carfilzomib. Mol Cancer Ther 12(Suppl. 11): C205–C205.
102. Rubnitz J. Inaba H. Dahl G. Ribeiro R. Bowman W. Taub J. et al. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML 02 multicentre trial. Lancet Oncol 11: 543–552.
103. Rytting M. Triche L. Thomas D. O'Brien S. Kantarjian H. (2014) Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood Cancer 61: 369–372.
104. Santi D. Norment A. Garrett C. (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993–6997.
105. Satwani P. Bhatia M. Garvin J. Jr George D. Dela Cruz F. Le Gall J. et al. (2012) A phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biol Blood Marrow Transplant 18: 324–329.
106. Schultz K. Bowman W. Aledo A. Slayton W. Sather H. Devidas M. et al. (2009) Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 27: 5175–5181.
107. Schultz K. Carroll A. Heerema N. Bowman W. Aledo A. Slayton W. et al. (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031. Leukemia 28: 1467–1471.
108. Seedhouse C. Das-Gupta E. Russell N. (2003) Methylation of the hMLH 1 promoter and its association with microsatellite instability in acute myeloid leukemia. Leukemia 17: 83–88.
109. Sekimizu M. Yamashita Y. Ueki H. Akita N. Hattori H. Maeda N. et al. (2013) Nilotinib monotherapy induced complete remission in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to imatinib and dasatinib. Leukemia Lymphoma 55: 1652–1653.
110. Siegel D. Martin T. Wang M. Vij R. Jakubowiak A. Lonial S. et al. (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120: 2817–2825.
111. Sievers E. Appelbaum F. Spielberger R. Forman S. Flowers D. Smith F. et al. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93: 3678–3684.
112. Sievers E. Larson R. Stadtmauer E. Estey E. Lowenberg B. Dombret H. et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19: 3244–3254.
113. Silverman L. Demakos E. Peterson B. Kornblith A. Holland J. Odchimar-Reissig R. et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429–2440.
114. Small D. Levenstein M. Kim E. Carow C. Amin S. Rockwell P. et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor / stem cells. Proc Natl Acad Sci USA 91: 459–463.
115. Smith B. Levis M. Beran M. Giles F. Kantarjian H. Berg K. et al. (2004) Single-agent CEP-701, a novel FLT 3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103: 3669–3676.
116. Soriano A. Yang H. Faderl S. Estrov Z. Giles F. Ravandi F. et al. (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302–2308.
117. Soverini S. de Benedittis C. Papayannidis C. Paolini S. Venturi C. Iacobucci I. et al. (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 120: 1002–1009.
118. Stone R. de Angelo D. Klimek V. Galinsky I. Estey E. Nimer S. et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT 3 respond to a small-molecule FLT 3 tyrosine kinase inhibitor, PKC412. Blood 105: 54–60.
119. Stresemann C. Bokelmann I. Mahlknecht U. Lyko F. (2008) Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 7: 2998–3005.
120. Stresemann C. Brueckner B. Musch T. Stopper H. Lyko F. (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794–2800.
121. Stumpel D. Schneider P. Seslija L. Osaki H. Williams O. Pieters R. et al. (2012) Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia 26: 682–692.
122. Tallman M. (2004) Acute promyelocytic leukemia as a paradigm for targeted therapy. Sem Hematol 41(2 Suppl. 4): 27–32.
123. Talpaz M. Shah N. Kantarjian H. Donato N. Nicoll J. Paquette R. et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531–2541.
124. Teachey D. Sheen C. Hall J. Ryan T. Brown V. Fish J. et al. (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination totreat acute lymphoblastic leukemia. Blood 112: 2020–2023.
125. Topp M. Gokbuget N. Zugmaier G. Degenhard E. Goebeler M. Klinger M. et al. (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120: 5185–5187.
126. Topp M. Kufer P. Gokbuget N. Goebeler M. Klinger M. Neumann S. et al. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493–2498.
127. Tsutsumi S. Taketani T. Nishimura K. Ge X. Taki T. Sugita K. et al. (2003) Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 63: 4882–4887.
128. Vrana J. Decker R. Johnson C. Wang Z. Jarvis W. Richon V. et al. (1999) Induction of apoptosis in U 937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016–7025.
129. Wang C. Mayo M. Baldwin A. Jr (1996) TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science 274: 784–787.
130. Wang M. Martin T. Bensinger W. Alsina M. Siegel D. Kavalerchik E. et al. (2013) Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 122: 3122–3128.
131. Wayne A. Bhojwani D. Silverman L. Richards K. Stetler-Stevenson M. Shah N. et al. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts 118 (21): 248.
132. Wayne A. Kreitman R. Findley H. Lew G. Delbrook C. Steinberg S. et al. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16: 1894–1903.
133. Wei G. Twomey D. Lamb J. Schlis K. Agarwal J. Stam R. et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL 1 and glucocorticoid resistance. Cancer Cell 10: 331–342.
134. Wei H. Xiang L. Wayne A. Chertov O. FitzGerald D. Bera T. et al. (2012) Immunotoxin resistance via reversible methylation of the DPH 4 promoter is a unique survival strategy. Proc Natl Acad Sci USA 109: 6898–6903.
135. Weisberg E. Liu Q. Nelson E. Kung A. Christie A. Bronson R. et al. (2012) Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT 3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia 26: 2233–2244.
136. Xu Q. Simpson S. Scialla T. Bagg A. Carroll M. (2003) Survival of acute myeloid leukemia cells requires PI 3 kinase activation. Blood 102: 972–980.
137. Yamamoto Y. Kiyoi H. Nakano Y. Suzuki R. Kodera Y. Miyawaki S. et al. (2001) Activating mutation of D 835 within the activation loop of FLT 3 in human hematologic malignancies. Blood 97:2434–2439.
138. Yang J. Wang Z. Fang Y. Jiang J. Zhao F. Wong H. et al. (2011) Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Disposition 39: 1873–1882.
139. Yee K. Zeng Z. Konopleva M. Verstovsek S. Ravandi F. Ferrajoli A. et al. (2006) Phase I / II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165–5173.
140. Yokoyama A. Lin M. Naresh A. Kitabayashi I. Cleary M. (2010) A higher-order complex containing AF 4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17: 198–212.
141. Zein N. Sinha A. McGahren W. Ellestad G. (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240: 1198–1201.
142. Zhang W. Konopleva M. Shi Y. McQueen T. Harris D. Ling X. et al. (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100: 184–198.
143. Zhang W. Xia X. Reisenauer M. Hemenway C. Kone B. (2006) Dot1a-AF9 complex mediates histone H 3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem 281: 18059–18068.
144. Zugmaier G. Handgretinger R. Locatelli F. Rizzari C. Trippett T. Borkhardt A. et al. (2013) A phase 1 / 2 study of blinatumomab in pediatric patients with relapsed / refractory B-cell precursor acute lymphoblastic leukemia. Blood 122 (21): 70.